

## 해외 바이오의약품 임상 현황 (2020.10.12~2020.10.18)

한국바이오의약품협회, 2020.10.20  
출처: ClinicalTrials.gov

### ○ 미국 19건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04580147	Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair	Retinal Detachment With Multiple Breaks, Unspecified Eye Proliferative Vitreoretinopathy	Drug: Intravitreal aflibercept injection Other: Sham control	M. Ali Khan, MD Southeastern Retina Associates Eye Associates of New Mexico University of California, Los Angeles Wills Eye	Phase 2
NCT04561206	Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma	Recurrent Classic Hodgkin Lymphoma	Drug: Brentuximab Vedotin Biological: Nivolumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2
NCT04510051	CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children	Malignant Brain Neoplasm Recurrent Malignant Brain Neoplasm Refractory Malignant Brain Neoplasm	Drug: Cyclophosphamide Drug: Fludarabine Biological: IL13Rα2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04441905	Phase 1 Study of SAR440894 vs Placebo	Chikungunya Virus Infection	Other: Placebo Biological: SAR440894	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04398680	A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Hepatic Function	Multiple Myeloma	Drug: Belantamab mafodotin	GlaxoSmithKline	Phase 1
NCT04312113	Angiographic Delivery of AD-MSC for Ulcerative Colitis	Ulcerative Colitis	Drug: Adipose derived, autologous mesenchymal stem cells	Mayo Clinic	Phase 1
NCT04225676	Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)	ALL	Biological: Tisagenlecleucel	Novartis Pharmaceuticals Novartis	Phase 2
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute	Phase 2
NCT04566445	HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005	Dry Age-related Macular Degeneration	Drug: GT005: Dose 1 Drug: GT005: Dose 2	Gyroscope Therapeutics	Phase 2
NCT04448834	Blinicyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphia CD19+ ALL	B-cell Acute Lymphoblastic Leukemia	Drug: Blinatumomab	David Rizzieri, MD Amgen Acrotech Biopharma Duke University	Phase 2
NCT04349280	A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer	Neoplasms	Drug: Bintrafusp alfa	GlaxoSmithKline Merck KGaA, Darmstadt, Germany	Phase 1
NCT04064190	Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition	Urothelial Carcinoma Recurrent Advanced Urothelial Carcinoma	Drug: Vactosertib(TEW-7197)/Durvalumab	MedPacto, Inc. AstraZeneca	Phase 2
NCT04585776	A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes	Type 1 Diabetes	Drug: LY900014 Drug: Insulin Degludec	Eli Lilly and Company	Phase 2
NCT04502082	Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)	Hepatocellular Carcinoma Liver Cancer Liver Neoplasm Metastatic Liver Cancer	Biological: ET140203 autologous T cell product	Eureka Therapeutics Inc.	Phase 1  Phase 2
NCT04426474	A Study of LY3502970 in Participants With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: LY3502970 Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04350138	Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection	Gonococcal Infection	Biological: Meningococcal Group B Vaccine Other: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
NCT04539470	Study to Evaluate the Safety and Pharmacokinetics of UTTR1147A in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Acute Graft-versus-host Disease	Drug: UTTR1147A	Genentech, Inc.	Phase 1
NCT04299048	Safety, Tolerability, PK and PD Following SC PF-06946860 in Patients With NSCLC and Cachexia	Cachexia Non-Small-Cell Lung Cancer	Drug: PF-06946860	Pfizer	Phase 1
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3

### ○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3

### ○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04547062	Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)	Acute Myeloid Leukemia (AML)	Drug: Tocilizumab	Nantes University Hospital	Phase 1
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3

## 해외 바이오의약품 임상 현황 (2020.10.12~2020.10.18)

한국바이오의약품협회, 2020.10.20  
출처: ClinicalTrials.gov

### ○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04582448	A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: Insulin icodec	Novo Nordisk A/S	Phase 1
NCT04426474	A Study of LY3502970 in Participants With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: LY3502970 Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04204616	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab	Galderma R&D	Phase 3

### ○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04507906	Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC	NSCLC Stage IV Checkpoint Inhibitor	Drug: Nivolumab Combined with Anlotinib	Shanghai Chest Hospital Bristol-Myers Squibb	Phase 1  Phase 2
NCT04361812	Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection	Similarity of Pharmacokinetics and Safety	Drug: HS632 Drug: Omalizumab (Xolair 藥)	Zhe Jiang Hisun Bioray Bio-pharmaceutical Co., Ltd	Phase 1
NCT04540211	A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma	Esophageal Cancer	Drug: Atezolizumab Drug: Tiragolumab Drug: Paclitaxel Drug: Cisplatin Drug: Atezolizumab Matching Placebo Drug: Tiragolumab Matching Placebo	Hoffmann-La Roche	Phase 3
NCT04456387	An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.	Hemophilia A	Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection	Zhengzhou Gensciences Inc Haimen Gensciences Inc	Phase 3